Futurehouse inspection of the Amnesty International tool for discovering “data -based” data “

Futurehouse, a non -profit institution with Eric Schmidt, which aims to build “Amnesty International” during the next decade, has released a new tool claiming to help support “data discovery” in biology. The new tool comes just a week after Futurehouse I launched API and platform.

The tool, called Finch, takes biological data (primarily in the form of research papers) and demanding (for example, “What can you tell me about the molecular motives of cancer meters?”)) And running the code before generating numbers and examining the results. in A series of posts on XThe founder and CEO of Futurehouse compared it to the company “Graduate Student in the first year”.

(B) EINIT is able to (do everything) in minutes is a great power, “Rodrichis wrote. “(Vinci) actually ends in fact finding some wonderful things (…) for our own projects internally, we found it very cool.”

Futurehouse proposal, such as dance a lotand a lot Emerging companies Technological giants, is that Finch and other artificial intelligence tools will lead to automating steps in the scientific process.

In an article earlier this yearThe CEO of Openai Sam Altman, “Superintelligent”, said of artificial intelligence can “greatly accelerate the scientific discovery and innovation.” Likewise, the CEO of anthropologist, who was launched only this week “Artificial Intelligence for Science” programSoldly predicted that artificial intelligence can Help formulate treatments for most types of cancer.

However, the evidence does not exist. Many researchers do not consider Amnesty International today especially useful In directing the scientific process. It is unfortunate that Futurehouse has not yet achieved a scientific penetration or a new discovery with artificial intelligence tools.

Biology, especially on the drug detection side, is an attractive goal for artificial intelligence companies. Priority research Estimates The market value was 65.88 billion dollars in 2024 and could reach 160.31 billion dollars by 2034.

Although there are some successes, artificial intelligence did not provide an immediate magic solution in the laboratory. Many companies that employ artificial intelligence to discover drugs, including Exscientia and BroachShe suffered High -level The failure of the clinical experience In recent years. Meanwhile, the accuracy of the leadership of artificial intelligence systems to discover medicines, such as Google DeepMind’s Alfafold 3and It tends to vary widely.

Rodrichis, Vinci, said, “ridiculous mistakes” – that is why Futurehouse is recruiting biotechnologists and alternative organizers to help assess its accuracy, reliability and training while it is in a closed house.

People can interested Subscribe here.